Similar articles

• Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.

  Yan L, Xing Z, Guo Z, Fang Z, Jiao W, Guo X, Xu Z, Fang Z, Liu Z. Yan L, et al. PLoS One. 2013;8(2):e55790. doi: 10.1371/journal.pone.0055790. Epub 2013 Feb 7. PLoS One. 2013. Retraction in: PLoS One. 2024 Feb 26;19(2):e0299822. doi: 10.1371/journal.pone.0299822. PMID: 23409045 Free PMC article. Retracted.
• Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin.

  Liu Z, Marquez M, Nilsson S, Holmberg AR. Liu Z, et al. Oncol Rep. 2009 Dec;22(6):1451-8. doi: 10.3892/or_00000587. Oncol Rep. 2009. PMID: 19885599
• Proteomic Analysis of a Human Prostate Cancer Cell Line after Incubation with a Novel Somatostatin14 Derivative.

  Liu Z, Mrquez M, Nilsson S, Holmberg AR, Alaiya A. Liu Z, et al. Cancer Genomics Proteomics. 2005 Nov-Dec;2(6):347-352. Epub 2005 Nov 1. Cancer Genomics Proteomics. 2005. PMID: 31394651
• Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer.

  Mosca A, Dogliotti L, Berruti A, Lamberts SW, Hofland LJ. Mosca A, et al. Dig Liver Dis. 2004 Feb;36 Suppl 1:S60-7. doi: 10.1016/j.dld.2003.11.021. Dig Liver Dis. 2004. PMID: 15077913 Review.
• Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.

  Damodaran S, Lang JM, Jarrard DF. Damodaran S, et al. J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. J Urol. 2019. PMID: 30747897 Review.